Global Maternal Pertussis Vaccine for Newborn Protection Market Strategic Research Report

Scope of the Report

The global Maternal Pertussis Vaccine for Newborn Protection market size is predicted to grow from US$ 5,834 million in 2025 to US$ 7,454 million in 2032; it is expected to grow at a CAGR of 3.6% from 2026 to 2032.

In 2024, global Maternal Pertussis Vaccine for Newborn Protection production reached approximately 350 million doses, with an average global market price of around US$ 16 per square meter. Maternal Pertussis Vaccine for Newborn Protection is a vaccine that protects against whooping cough. There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. In this report, we cover all the pertussis-containing vaccines. Gross margin for the Maternal Pertussis Vaccine for Newborn Protection in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.

The global Maternal Pertussis Vaccine for Newborn Protection market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The Maternal Pertussis Vaccine for Newborn Protection industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for Maternal Pertussis Vaccine for Newborn Protections is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Maternal Pertussis Vaccine for Newborn Protection market?

What factors are driving Maternal Pertussis Vaccine for Newborn Protection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Maternal Pertussis Vaccine for Newborn Protection market opportunities vary by end market size?

How does Maternal Pertussis Vaccine for Newborn Protection break out by Type, by Application?

This report presents a comprehensive overview of the global Maternal Pertussis Vaccine for Newborn Protection market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• DTaP
• Tdap
• DTwP

Segment by Composition

• Acellular Vaccines
• Whole-cell Vaccines

Segment by User

• Below 12 Months
• Above 12 Months

Segment by Application

• Hospital
• Clinic

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Maternal Pertussis Vaccine for Newborn Protection market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, Clinic evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact